Evidence map›Paper›PMID 42294651›Full record

ArticleAntimicrobial agents and chemotherapy2026

Plasma and intrapulmonary pharmacokinetics of funobactam, a novel diazabicyclooctane β-lactamase inhibitor, administered in combination with imipenem/cilastatin in healthy subjects.

Keith Rodvold, Mark Gotfried, Aramayis Kocharyan, Grigor Mamikonyan, Qifeng Shi, Hui Zhao, Ting Hu, Allan Xu, Meijie Le, Jianguo Li

Abstract readClinical Trial, Phase I
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Keith RodvoldUniversity of Illinois Chicago, Chicago, Illinois, USA.ORCID 0000-0002-7200-7346
Mark GotfriedPulmonary Associates, PA, Phoenix, Arizona, USA.
Aramayis KocharyanClinartis LLC, Hollywood, Florida, USA.
Grigor MamikonyanClinartis LLC, Hollywood, Florida, USA.
Qifeng ShiEvopoint Biosciences Co., Ltd., Suzhou, China.
Hui ZhaoEvopoint Biosciences Co., Ltd., Suzhou, China.
Ting HuEvopoint Biosciences Co., Ltd., Suzhou, China.
Allan XuKeystone Boanalytical, LLC, North Wales, Pennsylvania, USA.
Meijie LeEvopoint Biosciences Co., Ltd., Suzhou, China.
Jianguo LiEvopoint Biosciences USA, Inc., Massachusetts, USA.ORCID 0009-0007-7587-5476

Funding

Evopoint Biosciences USA, Inc Pulmonary Penetration Study
6 · The paper itself

Abstract

Funobactam (formerly XNW4107) is a novel non-β-lactam diazabicyclooctane β-lactamase inhibitor with potent direct activity against Ambler classes A, C, and D β-lactamases. Imipenem in combination with funobactam exhibits robust activity against carbapenem-resistant

Indexed as

Anti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase InhibitorsCilastatinImipenemAdultArea Under CurveBronchoalveolar Lavage FluidCilastatin, Imipenem Drug CombinationFemaleHealthy VolunteersHumansLungMacrophages, AlveolarMaleMiddle AgedAnti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase InhibitorsCilastatinCilastatin, Imipenem Drug CombinationImipenemalveolar macrophagesepithelial lining fluidfunobactamintrapulmonary pharmacokineticsXNW4107

Identifiers

PMID42294651
PMCPMC13435829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.